Ligand id: 7302

Name: terazosin

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: terazosin

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 103.77
Molecular weight 387.19
XLogP 2.32
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used to treat hypertension (not recommended as a first-line therapy) and urinary retention caused by benign prostatic hyperplasia (BPH).
Mechanism Of Action and Pharmacodynamic Effects
Terazosin is a selective α1-adrenoceptor antagonist. It blocks the action of endogenous adrenaline on smooth muscle cells within walls of the bladder and blood vessels. The drug has a relaxation effect on bladder wall musculature and blood vessels. This effect on peripheral blood vessel walls reduces blood pressure. Terazosin relaxes prostatic and urethral smooth muscle thereby improving urinary tract flow in BPH patients.
External links